There are 805 resources available
57O - A phase I/II multicenter, first-in-human study of DB-1311/BNT324 (a novel B7H3 ADC) in patients with advanced solid tumors
Presenter: Aaron Lisberg
Session: Proffered Paper session: Developmental and precision medicine
Resources:
Abstract
LBA8 - Phase II trial of atezolizumab plus carboplatin and paclitaxel in patients with metastatic or recurrent thymic carcinoma: Marble study
Presenter: Tomoyasu Mimori
Session: Proffered Paper session: Thoracic malignancies
Resources:
Abstract
1O - A prognostic value of BCT gene score in ER+HER2- breast cancer patients with 21-gene recurrence score
Presenter: Sung Gwe Ahn
Session: Proffered Paper session: Breast cancer
Resources:
Abstract
58O - Clinical efficacy, safety, and PK/PD from the first in human study of BM201, a TLR7/8 agonist
Presenter: Rutian Li
Session: Proffered Paper session: Developmental and precision medicine
Resources:
Abstract
625O - Efficacy and safety of lucitanib (AL3810) in second or subsequent-line treatment of advanced recurrent or metastatic thymic carcinoma: A randomized, double-blind, placebo-controlled multicenter phase II trial
Presenter: Wentao Fang
Session: Proffered Paper session: Thoracic malignancies
Resources:
Abstract
36O - <sup>18</sup>F-fluoroestradiol (<sup>18</sup>F-FES) PET/CT guided first-line treatment for HR+/HER2- metastatic breast cancer patients: Experience from real-world
Presenter: Biyun Wang
Session: Proffered Paper session: Breast cancer
Resources:
Abstract
27O - Assessment of overall survival benefit from neoadjuvant chemotherapy in elderly HER-2 negative breast cancer patients: A population-based study
Presenter: Wenjie Lv
Session: Proffered Paper session: Breast cancer
Resources:
Abstract
478O - Updated results of oral PD-L1 inhibitor ABSK043 in advanced solid tumor patients (pts) from a phase I study
Presenter: Shun Lu
Session: Proffered Paper session: Developmental and precision medicine
Resources:
Abstract
LBA5 - Zongertinib in patients with HER2-mutant NSCLC: Updated analysis of beamion LUNG-1
Presenter: Noboru Yamamoto
Session: Proffered Paper session: Thoracic malignancies
Resources:
Abstract
2O - Analysis of Asian and non-Asian patients (pts) from the NATALEE trial of ribociclib (RIB) + a nonsteroidal aromatase inhibitor (NSAI) in pts with HR+/HER2− early breast cancer (EBC)
Presenter: Yen-Shen Lu
Session: Proffered Paper session: Breast cancer
Resources:
Abstract